John M. Leonard's most recent trade in IQVIA Holdings Inc was a trade of 1,592 Common Stock done . Disclosure was reported to the exchange on April 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| IQVIA Holdings Inc | John M. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2025 | 1,592 | 15,375 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 196,000 | 196,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 136,000 | 1,077,115 (2%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 03 Jan 2025 | 26,807 | 941,115 (1%) | 0% | 12.2 | 326,509 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 7,850 | 967,922 (1%) | 0% | - | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 7,850 | 0 | - | - | Restricted Stock Unit | |
| IQVIA Holdings Inc | John M. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 1,047 | 13,783 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 163,929 | 163,929 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 113,586 | 960,072 (1%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | M. John Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 29.46 per share. | 03 Jan 2024 | 19,223 | 846,486 (1%) | 0% | 29.5 | 566,310 | Common Stock |
| Intellia Therapeutics Inc | Leonard John M. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 7,848 | 7,850 | - | - | Restricted Stock Unit | |
| Intellia Therapeutics Inc | M. Leonard John | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 7,848 | 865,709 (1%) | 0% | - | Common Stock | |
| IQVIA Holdings Inc | John M. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 1,063 | 12,736 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 128,631 | 128,631 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 91,036 | 857,861 (1%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 37.21 per share. | 04 Jan 2023 | 6,673 | 766,825 (1%) | 0% | 37.2 | 248,302 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 7,848 | 773,498 (1%) | 0% | - | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 7,848 | 15,698 | - | - | Restricted Stock Unit | |
| IQVIA Holdings Inc | John M. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 995 | 11,673 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 170.00 per share. | 30 Aug 2021 | 44,735 | 719,305 (1%) | 0% | 170 | 7,604,950 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 37,833 | 90,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 155.00 per share. | 30 Aug 2021 | 37,833 | 719,305 (1%) | 0% | 155 | 5,864,115 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 30 Aug 2021 | 37,833 | 757,138 (1%) | 0% | 14.6 | 551,605 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.46 per share. | 30 Aug 2021 | 28,750 | 748,055 (1%) | 0% | 23.5 | 674,475 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 28,750 | 0 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 27,167 | 127,833 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 30 Aug 2021 | 27,167 | 758,109 (1%) | 0% | 14.6 | 396,095 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.30 per share. | 30 Aug 2021 | 15,985 | 764,040 (1%) | 0% | 18.3 | 292,526 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 15,985 | 11,515 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 155.70 per share. | 30 Aug 2021 | 15,567 | 730,725 (1%) | 0% | 155.7 | 2,423,782 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2021 | 11,637 | 212,501 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 30 Aug 2021 | 11,637 | 730,942 (1%) | 0% | 13.4 | 155,936 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 154.98 per share. | 30 Aug 2021 | 7,428 | 746,292 (1%) | 0% | 155.0 | 1,151,191 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 156.96 per share. | 30 Aug 2021 | 4,758 | 725,967 (1%) | 0% | 157.0 | 746,816 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 157.75 per share. | 30 Aug 2021 | 3,123 | 722,844 (1%) | 0% | 157.7 | 492,653 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 159.18 per share. | 30 Aug 2021 | 2,598 | 720,246 (1%) | 0% | 159.2 | 413,550 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 153.66 per share. | 30 Aug 2021 | 2,334 | 753,720 (1%) | 0% | 153.7 | 358,642 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 152.81 per share. | 30 Aug 2021 | 2,055 | 756,054 (1%) | 0% | 152.8 | 314,025 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 159.98 per share. | 30 Aug 2021 | 725 | 719,521 (1%) | 0% | 160.0 | 115,986 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 160.69 per share. | 30 Aug 2021 | 216 | 719,305 (1%) | 0% | 160.7 | 34,709 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2021 | 27,139 | 224,138 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 23 Aug 2021 | 27,139 | 746,444 (1%) | 0% | 13.4 | 363,663 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 151.54 per share. | 23 Aug 2021 | 18,874 | 727,570 (1%) | 0% | 151.5 | 2,860,166 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 153.08 per share. | 23 Aug 2021 | 8,165 | 719,405 (1%) | 0% | 153.1 | 1,249,898 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 153.52 per share. | 23 Aug 2021 | 100 | 719,305 (1%) | 0% | 153.5 | 15,352 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 22,682 | 251,277 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 19 Aug 2021 | 22,682 | 741,987 (1%) | 0% | 13.4 | 303,939 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 150.46 per share. | 19 Aug 2021 | 9,726 | 732,261 (1%) | 0% | 150.5 | 1,463,374 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 151.56 per share. | 19 Aug 2021 | 6,993 | 725,268 (1%) | 0% | 151.6 | 1,059,859 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 152.30 per share. | 19 Aug 2021 | 5,963 | 719,305 (1%) | 0% | 152.3 | 908,165 | Common Stock |
| IQVIA Holdings Inc | John M. Leonard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 934 | 10,678 (0%) | 0% | 0 | Common Stock | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 15,937 | 15,937 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 13 Apr 2021 | 15,937 | 719,305 (1%) | 0% | 13.9 | 221,206 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 13 Apr 2021 | 10,000 | 703,368 (1%) | 0% | 6.8 | 68,300 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 188,363 | 188,363 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 31,394 | 31,394 | - | - | Restricted Stock Unit | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 56,718 | 68,516 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 05 Feb 2021 | 56,718 | 688,579 (1%) | 0% | 6.8 | 387,384 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.40 per share. | 05 Feb 2021 | 40,000 | 654,803 (1%) | 0% | 13.4 | 536,000 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 40,000 | 285,453 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 05 Feb 2021 | 28,043 | 660,536 (1%) | 0% | 75 | 2,103,225 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 67.86 per share. | 05 Feb 2021 | 14,018 | 632,742 (1%) | 0% | 67.9 | 951,261 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 67.18 per share. | 05 Feb 2021 | 8,043 | 646,760 (1%) | 0% | 67.2 | 540,329 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 68.78 per share. | 05 Feb 2021 | 881 | 631,861 (1%) | 0% | 68.8 | 60,595 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 01 Feb 2021 | 100,000 | 575,488 (1%) | 0% | 6.8 | 683,000 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 100,000 | 125,234 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 67,060 | 17,940 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 01 Feb 2021 | 67,060 | 651,661 (1%) | 0% | 13.9 | 930,793 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 60,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.78 per share. | 01 Feb 2021 | 60,000 | 598,814 (1%) | 0% | 22.8 | 1,366,800 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.78 per share. | 01 Feb 2021 | 50,000 | 615,599 (1%) | 0% | 22.8 | 1,139,000 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 73.00 per share. | 01 Feb 2021 | 36,858 | 614,803 (1%) | 0% | 73 | 2,690,634 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 72.00 per share. | 01 Feb 2021 | 30,998 | 584,601 (1%) | 0% | 72 | 2,231,856 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.30 per share. | 01 Feb 2021 | 30,000 | 557,954 (1%) | 0% | 18.3 | 549,000 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 30,000 | 27,500 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 64.13 per share. | 01 Feb 2021 | 26,058 | 532,680 (1%) | 0% | 64.1 | 1,671,100 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 63.32 per share. | 01 Feb 2021 | 16,750 | 558,738 (1%) | 0% | 63.3 | 1,060,610 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 64.10 per share. | 01 Feb 2021 | 16,640 | 571,074 (1%) | 0% | 64.1 | 1,066,624 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 63.30 per share. | 01 Feb 2021 | 11,100 | 587,714 (1%) | 0% | 63.3 | 702,630 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.88 per share. | 01 Feb 2021 | 10,000 | 533,853 (1%) | 0% | 13.9 | 138,800 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 10,000 | 85,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 64.09 per share. | 01 Feb 2021 | 9,432 | 542,074 (1%) | 0% | 64.1 | 604,497 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 01 Feb 2021 | 8,827 | 523,853 (1%) | 0% | 65 | 573,755 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 63.29 per share. | 01 Feb 2021 | 6,448 | 551,506 (1%) | 0% | 63.3 | 408,094 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.04 per share. | 01 Feb 2021 | 5,475 | 565,599 (1%) | 0% | 65.0 | 356,094 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 64.16 per share. | 01 Feb 2021 | 3,497 | 528,647 (1%) | 0% | 64.2 | 224,368 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.03 per share. | 01 Feb 2021 | 3,260 | 538,814 (1%) | 0% | 65.0 | 211,998 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 63.24 per share. | 01 Feb 2021 | 1,709 | 532,144 (1%) | 0% | 63.2 | 108,077 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 65.02 per share. | 01 Feb 2021 | 693 | 527,954 (1%) | 0% | 65.0 | 45,059 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2020 | 20,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 39.00 per share. | 27 Nov 2020 | 20,000 | 467,352 (0%) | 0% | 39 | 780,000 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.58 per share. | 27 Nov 2020 | 20,000 | 487,352 (0%) | 0% | 14.6 | 291,600 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 38.00 per share. | 27 Nov 2020 | 15,000 | 467,352 (0%) | 0% | 38 | 570,000 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2020 | 15,000 | 57,500 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.30 per share. | 27 Nov 2020 | 15,000 | 482,352 (0%) | 0% | 18.3 | 274,500 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2020 | 50,000 | 225,234 | - | - | Stock Option (right to buy) | |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 36.00 per share. | 25 Nov 2020 | 50,000 | 467,352 (0%) | 0% | 36 | 1,800,000 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.83 per share. | 25 Nov 2020 | 50,000 | 517,352 (1%) | 0% | 6.8 | 341,500 | Common Stock |
| Intellia Therapeutics Inc | John M. Leonard | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.00 per share. | 16 Nov 2020 | 20,000 | 467,352 (0%) | 0% | 34 | 680,000 | Common Stock |